GRAL — GRAIL, Inc.
Is GRAL overbought or oversold? Here is the current MarketMoodz read.
GRAIL, Inc. (GRAL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $105.60. The rating moved from Strong Oversold to Oversold on November 12, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$105.60
- Last changeMoved from Strong Oversold to Oversold on November 12, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
GRAIL, Inc. exhibits differentiated technology in the multi-cancer early detection space with meaningful long-term market potential, but near-term performance hinges on payer coverage, regulatory outcomes and continued commercial adoption. The market environment is currently cautious and favors large-cap defensive healthcare exposures, which may mute speculative upside for smaller diagnostics names. Limited recent public disclosure and subdued social sentiment increase information risk. Positive catalysts include broader payer acceptance, strong real-world performance data, and strategic partnerships or M&A interest; downside scenarios center on reimbursement setbacks, regulatory delays, or the need for additional financing.
Key factors
- Market position in multi-cancer early detection and diagnostic innovation provides differentiated product offering and potential long-term addressable market.
- Commercialization progress and payer coverage are critical drivers of revenue visibility; adoption trends and reimbursement decisions will materially affect near-term cash flow.
- Limited recent public filings and sparse social sentiment create information asymmetry, increasing reliance on commercial and regulatory milestones for valuation moves.
- Macro tone is cautiously risk-on with defensive flows into large-cap pharma; this environment may limit broad speculative biotech upside in the near term.
- Potential for partnerships or M&A interest from large-cap pharma or diagnostics players, which could be a catalyst for valuation re-rating.
- Insider activity (Form 4) recently filed; no large public filings altering financial disclosures in the assessment window.
Risks
- Reimbursement and payer pushback on multi-cancer screening tests, limiting commercial uptake and revenue growth.
- Regulatory hurdles or adverse labeling/coverage decisions that could delay or restrict market access.
- Competitive pressure from incumbent diagnostics companies and other multi-cancer early detection developers driving pricing and market share risk.
- Cash burn and financing risk if commercial ramp slows; potential dilution from capital raises if runway tightens.
- Policy and antitrust environment in healthcare creating execution uncertainty for partnerships or distribution agreements.
- Low visibility from limited recent public filings and sparse social sentiment, increasing short-term volatility and information risk.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for GRAL — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.